Neuraxis Inc (NRXS)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$5.96-1.81%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRXS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.5% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NRXS — dividend update
Dated 2026-07-10
Other Events On July 9, 2026, the Board of Directors of Neuraxis, Inc. (the “ Company ”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for the second quarter of 2026 (the “ Second Quarter Dividend ”). The Second Quarter Dividend will be paid in the form of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The number of shares of Common Stock to b…
Why it matters: Smaller operating losses show that Neuraxis is controlling costs well. This is important for staying strong long-term.
Supportive ifOperating losses in Q2 improve by at least 15% compared to Q1 2026.
Worry ifOperating losses worsen or improve by less than 5% in Q2.
Why it matters: Smaller losses show better cost control. This means the company is running more efficiently.
Supportive ifOperating losses improve to less than -$1.5 million.
Worry ifOperating losses worsen to more than -$2 million.
Why it matters: A drop below median growth could signal a slowdown in the healthcare sector, affecting Neuraxis.
Worry ifSector revenue growth drops below its median.
Less concerning ifSector revenue growth stays above its median.
Why it matters: If the healthcare sector shows renewed growth, it could benefit Neuraxis. A stronger sector can lift investor confidence.
Supportive ifHealthcare sector revenue growth reported above 9% year over year.
Worry ifHealthcare sector revenue growth reported below 9% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $635 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,953 loss on $10,000 · 39.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Strong revenue growth signals that Neuraxis is on track with its growth strategy. This would confirm positive momentum.
Supportive ifQ2 revenue growth exceeds 65% compared to Q2 2025.
Worry ifQ2 revenue growth is less than 50% year over year.
Why it matters: Changes to the dividend policy may show management's trust in cash flow and growth.
Watch forAnnouncement of an increase in the stock dividend.
Also watch forAnnouncement of a decrease or suspension of the stock dividend.
Why it matters: Higher losses show Neuraxis may have trouble managing costs. This could hurt future growth.
Worry ifOperating losses were worse than negative $2.12 million in Q3.
Less concerning ifOperating losses were at or below negative $2.12 million in Q3.
Why it matters: Meeting or exceeding this revenue target shows Neuraxis is on track with its growth goals.
Supportive ifQ3 revenue reported at more than $1.6 million.
Worry ifQ3 revenue reported below $1.6 million.
Why it matters: A drop in cash reserves may mean Neuraxis has money problems. This can affect operations.
Worry ifCash reserves were below $7.1 million.
Less concerning ifCash reserves reported at or above $7.1 million.